Travere Therapeutics Announces Topline Results from
The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended...
Source: globenewswire.com
Page 8 - Upper Limit News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Upper Limit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Upper Limit Today - Breaking & Trending Today
Travere Therapeutics Announces Interim Analysis from the
FILSPARI demonstrated a statistically significant, rapid, and sustained decline of proteinuria compared to the active control...
Source: globenewswire.com
Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023
SAN DIEGO, April 01, 2023 -- Travere Therapeutics, Inc. today announced publication in The Lancet of the interim analysis of efficacy and safety data from the ongoing pivotal, Phase 3 PROTECT... | April 1, 2023
Source: marketscreener.com
Travere Therapeutics, Inc.: Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023
SAN DIEGO, April 01, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced publication in The Lancet of the interim analysis of efficacy and safety data from the ongoing pivotal
Source: finanznachrichten.de
Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023
SAN DIEGO, March 23, 2023 -- Travere Therapeutics, Inc. today announced that the interim analysis of efficacy and safety data from the ongoing Phase 3 PROTECT Study evaluating... | March 23, 2023
Source: marketscreener.com